With the development and initial characterization of KL-11743, Olszewski et al. [26] suggested therapeutic potential for use of glucose uptake inhibition with SDHB-mutant tumors for a bioenergetic lethality and demonstrated decreased proliferation with KL-11743 treatment in these tumor types. This evidence concerns the gene SDHB and neoplasm.